Kisspeptin-10 research protocols: GPR54 signalling and the HPG axis

Kisspeptin-10 is the C-terminal decapeptide fragment of kisspeptin-54, the product of the KISS1 gene. It retains full agonist activity at KISS1R, the G-protein-coupled receptor still widely referred to by its original orphan designation GPR54. The discovery that inactivating mutations in GPR54 cause hypogonadotropic hypogonadism made this receptor one of the most consequential findings in reproductive endocrinology of the last quarter century.

Position in the HPG cascade

The hypothalamic-pituitary-gonadal axis runs in a strict hierarchy, and kisspeptin sits above the classical entry point:

1. Kisspeptin neurons in the arcuate nucleus and the anteroventral periventricular nucleus release kisspeptin.
2. Kisspeptin binds KISS1R on GnRH neurons, depolarising them and triggering GnRH release.
3. GnRH reaches the anterior pituitary through the hypophyseal portal system and stimulates gonadotrophs.
4. The pituitary releases LH and FSH.
5. LH and FSH act on the gonads, driving steroidogenesis and gametogenesis.

Because kisspeptin acts one level above GnRH, it is the tool of choice for asking whether a given phenotype originates upstream or downstream of GnRH neurons. If kisspeptin administration restores LH pulsatility, the GnRH neurons are intact and the defect is upstream. If it does not, the lesion is at or below the GnRH neuron.

Half-life constrains the experiment

Kisspeptin-10 clears rapidly. Reported circulating half-life for the decapeptide is in the range of a few minutes, substantially shorter than kisspeptin-54, which persists longer. Two design consequences follow directly:

• Bolus administration produces a sharp, transient LH response. Sampling windows in published protocols are correspondingly tight, often minutes rather than hours.
• Continuous infusion produces receptor desensitisation. Sustained KISS1R occupancy downregulates the response, an effect documented across multiple models. Intermittent administration preserves responsiveness.

This desensitisation behaviour is itself a research subject, since it mirrors the well-established desensitisation seen with continuous GnRH agonist exposure.

Reconstitution for a 10 mg vial

Our Kisspeptin-10 ships as a 10 mg lyophilized vial, 99.688% HPLC purity on the current lot. Standard preparations:

One handling note specific to this peptide: kisspeptin-10 contains a C-terminal amide and is prone to aggregation at high concentration in low-ionic-strength solution. If you observe cloudiness, prepare a more dilute stock rather than attempting to redissolve by vortexing.

What the published record reports

Human clinical research on kisspeptin, principally at Imperial College London and collaborating centres, has examined kisspeptin administration in the context of reproductive endocrine assessment and IVF trigger protocols, with published reports of LH surge induction. That work is conducted under regulated clinical trial conditions with pharmaceutical-grade material. It is not a template for anything else, and material supplied as a research reference standard is not clinical-trial material.

Sourcing and verification

Purity matters more than any protocol detail. A concentration curve computed from a vial that is 88% peptide and 12% truncated sequence is not reproducible, and the failure is invisible until you compare it against another lot. Every Lumera Labs lot ships with a lot-specific certificate of analysis reporting HPLC-UV purity, and those certificates are posted publicly at Lab Results before you order, not emailed afterward. Orders ship from within Canada in 24 to 48 hours, free over $200 CAD, so there is no customs exposure and no multi-week transit window for temperature-sensitive material.

FAQ